OC GCP Questions From:

To:

GCP for storage and distribution

Subject: Tuesday, April 22, 2014 12:09:46 PM Date:

## Good afternoon -

The general requirements for storage are distribution are below –

Under FDA regulations 21 CFR 312.61 states -

Control of the investigational drug. --

An investigator shall administer the drug only to subjects under the investigator's personal supervision or under the supervision of a sub-investigator responsible to the investigator. The investigator shall not supply the investigational drug to any person not authorized under this part to receive it.

## 312.62 Investigator recordkeeping and record retention.

(a)Disposition of drug. An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subjects. If the investigation is terminated, suspended, discontinued, or completed, the investigator shall return the unused supplies of the drug to the sponsor, or otherwise provide for disposition of the unused supplies of the drug under 312.59.

## ICH E-6 – Good Clinical Practice-Consolidated Guidance

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf states --

## 4.6 Investigational Product(s)

- 4.6.1 Responsibility for investigational product(s) accountability at the trial site(s) rests with the investigator/institution.
- 4.6.2 Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institution's duties for investigational product(s)
- accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution.
- 4.6.3 The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain
- records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s). These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product(s) and trial subjects. Investigators should maintain records that document adequately that the subjects were provided the doses specified by the protocol and reconcile all investigational product(s) received from the sponsor.
- 4.6.4 The investigational product(s) should be stored as specified by the sponsor (see sections 5.13.2 and 5.14.3) and in accordance with applicable regulatory requirement(s).
- 4.6.5 The investigator should ensure that the investigational product(s) are used only in accordance with the approved protocol.
- 4.6.6 The investigator, or a person designated by the investigator/institution, should explain the correct use of the investigational product(s) to each subject and
- should check, at intervals appropriate for the trial, that each subject is following the instructions properly

As noted above, specific instructions for any investigational product storage would be the responsibility of the sponsor and the nature of the investigational product.

I hope this information is helpful. Please contact us again at <a href="mailto:qcp.questions@fda.hhs.gov">qcp.questions@fda.hhs.gov</a> should you have additional questions.

Kind regards,

Doreen M. Kezer, MSN

Senior Health Policy Analyst Office of Good Clinical Practice Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

**From:** [Redacted]

Sent: Sunday, April 20, 2014 9:20 PM

To: OC GCP Questions

**Subject:** GCP for storage and distribution

Dear FDA,

Please help to provide standard for storage and distribution of drug that used to trial on human.

Thank you very much.

[Redacted]